1. Home
  2. NIE vs ANNX Comparison

NIE vs ANNX Comparison

Compare NIE & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Equity & Convertible Income Fund of Beneficial Interest

NIE

Virtus Equity & Convertible Income Fund of Beneficial Interest

HOLD

Current Price

$26.09

Market Cap

726.3M

Sector

Finance

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.25

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIE
ANNX
Founded
2007
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
726.3M
812.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NIE
ANNX
Price
$26.09
$5.25
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$16.50
AVG Volume (30 Days)
48.9K
3.9M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
9.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16,320.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.78
$2.03
52 Week High
$27.24
$7.18

Technical Indicators

Market Signals
Indicator
NIE
ANNX
Relative Strength Index (RSI) 46.99 46.35
Support Level $25.99 $4.66
Resistance Level $26.98 $5.43
Average True Range (ATR) 0.41 0.45
MACD -0.05 -0.06
Stochastic Oscillator 42.86 23.08

Price Performance

Historical Comparison
NIE
ANNX

About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest

Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: